Add this topic to your myFT Digest for news straight to your inbox
Anglo-Swedish group overcomes first step towards approval for new cancer medicines
Regulatory breakthrough for Imfinzi follows disappointing results in earlier trial
London-listed pharmaceutical group’s shareholders are not happy with more of the same
International Edition